What is Amryt Pharma?
Amryt Pharma operates as a revenue-generating biotechnology enterprise dedicated to the acquisition, development, and commercialization of novel therapeutics for rare and orphan diseases. The company's portfolio is anchored by Lojuxta, an approved treatment for Homozygous Familial Hypercholesterolaemia, and a robust pipeline including AP101, a Phase 3 candidate for Epidermolysis Bullosa. By targeting niche patient populations, Amryt effectively mitigates competitive pressures while addressing severe, life-altering genetic disorders. Their strategic focus extends to next-generation peptide medicines and gene-therapy platforms, positioning the company at the intersection of advanced medical research and commercial scalability.
How much funding has Amryt Pharma raised?
Amryt Pharma has raised a total of $21.2M across 1 funding round:
Debt
$21.2M
Debt (2016): $21.2M with participation from European Investment Bank
Key Investors in Amryt Pharma
European Investment Bank
The European Investment Bank is the lending arm of the European Union, providing long-term financing and expertise for projects that contribute to EU policy objectives.
What's next for Amryt Pharma?
Looking ahead, the infusion of capital will likely be directed toward the completion of Phase 3 clinical trials for AP101 and the continued expansion of the company's gene-therapy platform, AP103. As Amryt Pharma transitions from a development-heavy entity to a more mature commercial organization, the focus will shift toward maximizing the market penetration of its existing assets while de-risking its early-stage pipeline. Investors should monitor the company's ability to navigate regulatory landscapes and its success in scaling distribution networks for its orphan drug portfolio, which remains the primary driver of long-term value creation in this high-stakes sector.
See full Amryt Pharma company page
